TriSalus Life Sciences (TLSIW) Change in Accured Expenses (2021 - 2026)

TriSalus Life Sciences (TLSIW) has 6 years of Change in Accured Expenses data on file, last reported at $160000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 90.15% year-over-year to $160000.0; the trailing twelve-month figure through Mar 2026 stood at $556000.0 (up 122.65% YoY), and the FY2025 full-year result was $2.0 million, up 146.08% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $160000.0, down from $692000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.4 million in Q4 2023 and bottomed at -$4.6 million in Q3 2023.
• The 5-year median for Change in Accured Expenses is $214728.0 (2022), against an average of $345882.4.
• The widest annual swing landed in 2022, when Change in Accured Expenses surged 1046.1%; it then sank 1486.36% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $4.1 million in 2022, then surged by 30.69% to $5.4 million in 2023, then sank by 94.43% to $301000.0 in 2024, then soared by 129.9% to $692000.0 in 2025, then sank by 76.88% to $160000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $160000.0 (Q1 2026), $692000.0 (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison